Cerecor (CERC) Receiving Somewhat Positive News Coverage, Report Shows

Media coverage about Cerecor (NASDAQ:CERC) has trended somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerecor earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8927318879608 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Cerecor (NASDAQ:CERC) traded up $0.04 during trading hours on Friday, reaching $2.74. 479,728 shares of the company traded hands, compared to its average volume of 859,399. The company has a market cap of $71.39, a P/E ratio of 274.27 and a beta of 2.95. Cerecor has a one year low of $0.34 and a one year high of $4.25.

Several analysts have recently issued reports on CERC shares. ValuEngine upgraded shares of Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet upgraded shares of Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.

In other news, major shareholder Armistice Capital Master Fund purchased 45,200 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The shares were bought at an average cost of $1.20 per share, for a total transaction of $54,240.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Armistice Capital, Llc purchased 35,200 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were purchased at an average price of $1.20 per share, for a total transaction of $42,240.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 95,485 shares of company stock worth $114,168 over the last quarter. 10.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Cerecor (CERC) Receiving Somewhat Positive News Coverage, Report Shows” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/14/cerecor-cerc-receiving-somewhat-positive-news-coverage-report-shows.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

What are top analysts saying about Cerecor? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerecor and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit